Vertex Pharmaceuticals (NASDAQ: VRTX) awards 31.56 deferred units to director

Q: What insider transaction did Vertex Pharmaceuticals (VRTX) director Alan M. Garber report?

Alan M. Garber reported receiving a grant of 31.56 deferred stock units tied to Vertex common stock. These units were awarded on July 15, 2026 as compensation and do not represent an open-market purchase or sale of Vertex shares.

Q: How many Vertex (VRTX) deferred stock units does Alan M. Garber hold after this Form 4 transaction?

After the reported grant, Alan M. Garber directly holds 65.458 deferred stock units linked to Vertex common stock. This total reflects the newly awarded 31.56 units plus previously accumulated units, as disclosed in the Form 4 filing.

Q: Did the Vertex (VRTX) Form 4 for Alan M. Garber involve open-market trading of common stock?

No. The Form 4 reports a grant (code “A”) of deferred stock units, a form of equity compensation. It does not report any open-market purchases (code “P”) or sales (code “S”) of Vertex common stock by Alan M. Garber.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.

Vertex Pharmaceuticals director Alan M. Garber received a grant of 31.56 deferred stock units on July 15, 2026. Each unit represents one share of common stock and will be paid in shares upon the earliest of his board service termination, a change of control, or his disability or death. Following this award, he directly holds 65.458 deferred stock units tied to Vertex common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Garber Alan M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	31.56	$475.28	$15K

Holdings After Transaction: Deferred Stock Units — 65.458 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Deferred stock units granted: 31.5600 units Grant value per unit: $475.2800 per unit Deferred stock units after transaction: 65.4580 units +1 more

4 metrics

Deferred stock units granted 31.5600 units Grant of deferred stock units to director Alan M. Garber on July 15, 2026

Grant value per unit $475.2800 per unit Transaction price per deferred stock unit for the July 15, 2026 award

Deferred stock units after transaction 65.4580 units Total deferred stock units directly held by Alan M. Garber following the grant

Unit-to-share ratio 1 unit : 1 share Each deferred stock unit represents one share of Vertex common stock

Key Terms

Deferred Stock Units, change of control, board of directors

3 terms

Deferred Stock Units financial

"Each deferred stock unit represents one share of common stock"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

change of control financial

"upon the earliest to occur of ... a change of control of our company"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

board of directors financial

"termination of Dr. Garber's service on our board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 04:06 PM Accepted by SEC EDGAR 07/17/2026 - 04:05 PM

FAQ

What insider transaction did Vertex Pharmaceuticals (VRTX) director Alan M. Garber report?

Alan M. Garber reported receiving a grant of 31.56 deferred stock units tied to Vertex common stock. These units were awarded on July 15, 2026 as compensation and do not represent an open-market purchase or sale of Vertex shares.

How many Vertex (VRTX) deferred stock units does Alan M. Garber hold after this Form 4 transaction?

After the reported grant, Alan M. Garber directly holds 65.458 deferred stock units linked to Vertex common stock. This total reflects the newly awarded 31.56 units plus previously accumulated units, as disclosed in the Form 4 filing.

What does each deferred stock unit reported by Vertex (VRTX) for Alan M. Garber represent?

Each deferred stock unit reported for Alan M. Garber represents one share of Vertex common stock. The units are not paid immediately in cash; instead, they convert into an equivalent number of common shares when specified future events occur.

When will Alan M. Garber’s Vertex (VRTX) deferred stock units be paid out in shares?

The deferred stock units will be paid out in Vertex common stock upon the earliest of Dr. Garber’s board service termination, a change of control of the company, or Dr. Garber’s disability or death, according to the Form 4 footnote.

Did the Vertex (VRTX) Form 4 for Alan M. Garber involve open-market trading of common stock?

No. The Form 4 reports a grant (code “A”) of deferred stock units, a form of equity compensation. It does not report any open-market purchases (code “P”) or sales (code “S”) of Vertex common stock by Alan M. Garber.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garber Alan M

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	⁽¹⁾	07/15/2026		A		31.56		⁽¹⁾	⁽¹⁾	Common Stock	31.56	$475.28	65.458	D

Explanation of Responses:

1. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR